• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Emergent BioSolutions

    Reed-Lane

    PCI Pharma Services

    Alcami

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Syngene

    Baxter BioPharma Solutions

    Reed-Lane

    Adare Pharma Solutions

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Top Companies Report

    13 Gilead Sciences

    ...

    13 Gilead Sciences
    At the time of press, Gilead's remdesivir is the only drug approved for use as a treatment against Covid-19.
    Kristin Brooks, Managing Editor07.15.20
    Headquarters: Foster City, CA
    twitter.com/gileadsciences
    www.gilead.com


    Headcount: 12,000
    Year Established: 1987
    Revenues:  $22,449  (+1%)
    Net Income:  $5,364  (-2%)
    R&D:  $9,106  (+81%)

    TOP SELLING DRUGS  
    Drug Indication  2019 Sales  (+/-%)
    Biktarvy  HIV-1 treatment $4,738  300%
    Genvoya HIV treatment $3,93 -15%
    Truvada  HIV treatment $2,813 -6%
    Epclusa Hepatitis C treatment  $1,965 0%
    Odefsey HIV treatment $1,655  4%
    Descovy  HIV PrEP $1,500  -5%
    Harvoni Hepatitis C treatment $643 -47%
    Letairis pulmonary arterial hypertension $618 -34%
    Atripla  HIV treatment  $600 -50%
    Vemlidy  Hepatitis B treatment  $488 52%


    Despite a relatively flat fiscal year, Gilead continues to make pipeline progress, along with efforts to diversify its portfolio, and further expand into immuno-oncology with significant investments, namely the acquisition of Forty Seven and an extensive alliance with Arcus Biosciences.

    Looking ahead, in the first quarter of 2020 revenues were up 5% driven by HIV product sales of $4.1 billion, up 14% thanks to continued uptake of Biktarvy with $1.7 billion in sales, and the company’s CAR-T cancer therapy Yescarta, which generated $140 million in sales in the quarter compared to $96 million in 1Q19. There’s reason to believe the company’s flagship HIV franchise and foray into CAR-T therapies will more than compensate for continued declines in chronic hepatitis C virus (HCV) sales, which were down 8% in 1Q20.

    Top News
    As one of the foremost anti-viral experts in the industry, it’s not surprising that the company succeeded in being the first to provide a potential therapy for COVID-19. Remdesivir was approved in Japan on May 7 under an exceptional approval pathway as a treatment for patients infected with SARS-CoV-2. The FDA has granted the drug an Emergency Use Authorization for the treatment of hospitalized patients with severe COVID-19, however the authorization is temporary.

    Remdesivir is an investigational nucleotide analog with broad-spectrum antiviral activity both in vitro and in vivo in animal models against multiple emerging viral pathogens, including Ebola, Marburg, MERS and SARS.

    On June 1, Gilead announced results from the Phase III trial of Remdesivir in patients with moderate COVID-19. The SIMPLE trial in hospitalized patients with moderate COVID-19 pneumonia evaluated 5-day and 10-day courses of the investigational antiviral remdesivir plus standard of care, versus standard of care alone. The study demonstrated that patients in the 5-day remdesivir treatment group were 65 percent more likely to have clinical improvement at Day 11 compared with those in the standard of care group. The odds of improvement in clinical status with the 10-day treatment course of remdesivir versus standard of care were also favorable, trending toward but not reaching statistical significance.

    In an effort to expand access to the investigational remdesivir for the potential treatment of COVID-19, Gilead entered a global collaboration and license agreement with Mylan, giving Mylan rights to manufacture and distribute remdesivir in 127 low- and middle-income countries, including India. To ensure preparedness, Mylan will develop a bioequivalent version of the drug, including production of its own active pharmaceutical ingredient and finished dosage form in sterile powder lyophilized vials for intravenous infusion.

    Expanded Approvals & Filings
    Marking a couple of significant approvals for the company, the FDA approved a pre-exposure prophylaxis (PrEP) indication for Descovy to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents who are HIV-negative and at-risk, which was approved under a priority review designation.

    The FDA also approved Epclusa for children ages 6 and older with Hepatitis C Virus. Epclusa is the first pan-genotypic, protease inhibitor-free regimen approved in the U.S. for children and adults. An estimated 23,000 to 46,000 children in the U.S. are living with HCV.

    Reaching a key milestone, Gilead submitted an NDA to the FDA for filgotinib, an investigational, oral, selective JAK1 inhibitor for the treatment of moderate-to-severe rheumatoid arthritis (RA). The filing is supported by a Phase III program, which met its primary endpoints and demonstrated durable efficacy and safety results across multiple RA patient populations.

    R&D Efforts
    Gilead is working on multiple investigational compounds for the treatment of advanced fibrosis due to Nonalcoholic Steatohepatitis (NASH), including firsocostat, cilofexor, and selonsertib. The company is evaluating single-agent and combination therapy approaches against the core pathways associated with NASH – hepatocyte lipotoxicity, inflammation and fibrosis.

    However, NASH, a complex disease driven by multiple mechanisms, is proving to be a challenge. Gilead’s Phase III STELLAR-3 study evaluating the safety and efficacy of selonsertib, an investigational, once daily, oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), for patients with bridging fibrosis due to NASH, did not meet the primary endpoint of a histologic improvement in fibrosis without worsening of NASH.

    Similarly, a Phase II ATLAS study of combination and monotherapy investigational treatments, firsocostat and cilofexor, in advanced fibrosis due to NASH, did not meet the primary endpoint, although some improvement was seen in response measures of fibrosis and liver function compared with placebo.

    Despite these disappointing results, the company says it remains focused and committed to developing effective treatments for patients living with advanced fibrosis due to NASH. Gilead is also collaborating with Novo Nordisk on a study combining Gilead’s cilofexor and firsocostat and Novo Nordisk’s semaglutide for the treatment of NASH.

    Among recent pipeline progress, in late May, Kite, a Gilead Company, reported positive interim analysis of ZUMA-5, a global Phase II study evaluating Yescarta in patients with relapsed or refractory indolent (slow growing) non-Hodgkin lymphoma (NHL) after at least two prior lines of therapy. After a single infusion of Yescarta, 93 percent of patients responded, with an impressive 80 percent achieving a complete response.

    Pending final results, Kite plans to submit a sBLA to the FDA later this year to expand the indication for Yescarta. If approved, it would become the first and only chimeric antigen receptor (CAR) T therapy approved for the treatment of relapsed or refractory indolent NHLs.

    Also, Kite achieved two key regulatory milestones for KTE-X19, an investigational cell therapy for the treatment of relapsed or refractory mantle cell lymphoma. In Europe, the marketing authorization application for KTE-X19 is under review, and in the U.S., the FDA accepted the Biologics License Application and it was granted Priority Review Designation.

    Investments
    Known for investing big in R&D, Gilead recently entered an agreement to acquire Forty Seven, Inc. in a transaction valued at approximately $4.9 billion. The acquisition strengthens Gilead’s immuno-oncology portfolio with the addition of Forty Seven’s investigational lead candidate, magrolimab, a monoclonal antibody in clinical development for the treatment of several cancers including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL).

    The investigational therapy targets CD47, a “do not eat me” signal that allows cancer cells to avoid destruction, allowing the patient’s own immune system to eradicate those cancer cells. A Phase 1b study of magrolimab in patients with MDS and AML showed the potential for it to be a first-in-class therapy.

    Gilead also recently entered a 10-year partnership with Arcus Biosciences valued at nearly $2 billion to develop current and future therapeutic candidates in Arcus’s pipeline of products that target key mechanisms involved in tumor evasion of the immune system, as well as drug candidates that target cell-intrinsic pathways important for cancer growth and metastasis. In addition to small molecule products, Arcus is also advancing antibody products that target immune checkpoint receptors, including PD-1 and TIGIT.

    Gilead gains rights to zimberelimab, as well as the right to opt-in to all other current Arcus clinical candidates, which include AB154, AB928 and AB680.

    Similarly, last July, Gilead entered a 10-year global research and development collaboration with Galapagos providing access to a portfolio of compounds, including six molecules currently in clinical trials, more than 20 preclinical programs and a proven drug discovery platform. Gilead paid $3.95 billion upfront and made a $1.1 billion equity investment in Galapagos in exchange for exclusive product license and option rights to develop and commercialize all current and future programs.

    Galapagos most advanced molecule, GLPG1690, is in Phase III development for idiopathic pulmonary fibrosis, which has shown a reduction in signs and symptoms of IPF. GLPG1972 is a Phase IIb candidate for osteoarthritis, and first-in-class compounds GLPG1690 and GLPG1972, could offer important mid- and late-stage pipeline opportunities for Gilead.

    Expanding Cell Therapy Efforts
    Lastly, several cell therapy alliances expand Gilead’s oncology efforts. A research pact with oNKo-innate aims to develop next-generation drug and engineered cell therapies focused on natural killer (NK) cells. Like T cells, NK cells are a class of white blood cells that play a critical surveillance and effector role in the immune system. Appropriately activated and targeted NK cells may represent a differentiated approach that would be potentially synergistic with T cell mediated anti-tumor strategies.

    Additionally, Kite and Teneobio entered into a license and collaboration agreement through which Kite will receive exclusive rights to certain antibodies directed to B-cell maturation antigen (BCMA). The fully human variable heavy chain of one such antibody is currently undergoing Phase I evaluation in a chimeric antigen receptor (CAR) format for the treatment of multiple myeloma. The companies are also working on the discovery of antibodies directed to four additional targets using Teneobio’s UniAb platform to be used in CAR-T cell therapies for multiple myeloma and other cancers.

    To accommodate this growing pipeline of cell therapies, Kite is building a new 67,000-sq.-ft. facility in Oceanside, CA, dedicated to the development and manufacture of viral vectors, a critical starting material in the production of cell therapies. 

    Related Top Companies Report

    • 25 CSL Behring

      25 CSL Behring

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 22 Astellas

      22 Astellas

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20

    • 21 Biogen

      21 Biogen

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.20.20


    • 12 Amgen

      12 Amgen

      ...
      Tim Wright, Editor, Contract Pharma 07.20.20

    • 10 Bristol-Myers Squibb

      10 Bristol-Myers Squibb

      ...
      Kristin Brooks, Managing Editor, Contract Pharma 07.15.20

    • 03 Novartis

      03 Novartis

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • 02 Roche

      02 Roche

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 09 Takeda

      09 Takeda

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 01 Pfizer, Inc.

      01 Pfizer, Inc.

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20


    • The 2020 Top 25 Pharma and Biopharma Companies

      The 2020 Top 25 Pharma and Biopharma Companies

      Top 25 Pharma and Biopharma Companies (Based on 2019 Pharma/Biopharma Sales, in $U.S. Millions)
      Contract Pharma Staff 07.15.20

    • 08 GlaxoSmithKline

      08 GlaxoSmithKline

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 07 AbbVie

      07 AbbVie

      ...
      Kristin Brooks , Managing Editor, Contract Pharma 07.15.20


    • 06 Sanofi

      06 Sanofi

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 05 Merck

      05 Merck

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    • 04 Johnson & Johnson

      04 Johnson & Johnson

      ...
      Tim Wright, Editor, Contract Pharma 07.15.20

    Trending
    • Catalent Acquires Delphi Genetics
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Matica Biotechnology Breaks Ground On Cell And Gene Therapy Site
    • Celonic Group Announces Plans For New Facility In Switzerland
    • BMS Expands Cell Therapy Manufacturing Capabilities
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login